Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness/Biosite merger gets US OK:

This article was originally published in Clinica

Executive Summary

Inverness Medical Innovations' pending acquisition of San Diego, California-based diagnostics company Biosite has received the go-ahead from US antitrust authorities. The proposed transaction went through the 30-day waiting period required under the US Hart-Scott-Rodino Act without the company having to address any potential anti-competition concerns. Inverness' tender offer for Biosite shares, at $92.50 per share, is currently underway and scheduled to expire at midnight on June 25.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel